SemiNex Corporation debuts its new 1270nm laser wavelength at this year’s World of Photonics show in Munich. This new wavelength builds upon SemiNex’s prior range of 1300-1700nm and expands the company into new areas of the medical industry.
SemiNex teamed up with Veralase, LLC and Massachusetts General Hospital to develop an affordable hand-held laser device that operates at 1270nm. This specific wavelength has proven to enhance immune response to vaccines. This near-infrared laser treatment avoids side effects like soreness, inflammation, erythema and tissue damage that often occurs with chemical adjuvants. Under a U.S. National Institute of Health (NIH) grant received by Veralase, SemiNex continues to support the research of other optimal wavelengths and their potential clinical applications.
“SemiNex is proud to be a part of this groundbreaking medical research,” stated David Bean, President of SemiNex Corporation. “We are pleased to collaborate with Veralase and the amazing scientists at Massachusetts General Hospital.”
Another remarkable use for 1270nm is in creating different forms of oxygen. 1270nm irradiation in water causes photoactivation in the ground state of oxygen to create singlet oxygen. Singlet oxygen is a high energy form of oxygen which can be used in preparative organic chemistry and photodynamic therapy. The uses for singlet oxygen continue to be explored.
1270nm laser diodes set a new record at SemiNex for the highest powers and efficiencies to date. These added benefits of power and efficiency will enable customers to use small, efficient and relatively inexpensive laser diodes to develop products in many industries and applications. Dr. John Callahan, SemiNex’s Vice President of Engineering, explains, “With the new 1270nm projects, SemiNex has been able to work on optimizing high volume manufacturing processes to drive down cost and improve yields.”
Continuous improvement is a core value at SemiNex and the company plans to develop and fine-tune the new wavelength in response to customer and market needs. SemiNex is proud to be a part of improving worldwide healthcare and anticipates taking on new medical projects in the near future.
To discuss projects using the new 1270nm wavelength or any other of the company’s products, stop by and visit with us this week at Hall B3 / Booth 258 at World of Photonics in Munich or respond to the contact information below. We look forward to hearing from you!